[-] Show simple item record

dc.contributor.authorMazzone, Michael F.
dc.contributor.authorJamieson, Barbara
dc.date.issued2007-04eng
dc.description.abstractYes, warfarin is effective in the secondary prevention of venous thromboembolic events (VTEs) for patients positive for lupus anticoagulant or anticardiolipin antibody (also known as antiphospholipid antibodies [aPL]) (strength of recommendation [SOR]: B, single cohort study, extrapolation from other RCTs). Patients should be treated for at least a year (SOR: C, consensus statement), and possibly indefinitely, with warfarin (SOR: B, small clinical trials and cohort studies). Moderate-intensity therapy (international normalized ratio [INR] range, 2.0-3.0) appears to be the best balance between risks and benefits (SOR: B, based on meta-analysis of 2 small randomized control trials.en
dc.identifier.citationJournal of Family Practice, 56(4) 2007: 309+.en
dc.identifier.urihttp://hdl.handle.net/10355/3608
dc.publisherFamily Physicians Inquiries Networken
dc.relation.ispartofClinical Inquiries, 2007 (MU)en
dc.relation.ispartofcommunityUniversity of Missouri-Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Network
dc.subjectlupusen
dc.subjectanticardiolipin antibodyen
dc.subjectaspirinen
dc.subject.lcshWarfarinen
dc.subject.lcshPhospholipid antibodiesen
dc.subject.lcshCerebral embolism and thrombosis -- Preventionen
dc.titleDoes warfarin prevent venous thromboembolic events in aPL-positive patients?en
dc.typeArticleen


Files in this item

[PDF]

This item appears in the following Collection(s)

[-] Show simple item record